ÂÜŔňÂŇÂ×

Dana Hu-Lowe, Ph.D., is the VP of Global Product Team Leadership of Adagene. Dr. Hu-Lowe has more than 20 years of experience in oncology drug discovery, pharmacology, translational research, and clinical development, with over seven years of experience in project and strategic alliance management, and leadership of both preclinical and clinical product programs.

Before joining Adagene, Dr. Hu-Lowe was the Executive Director and Global Product Team Lead (GPTL) for enzolvantinib and TPX-0046 at Turning Point Therapeutics, responsible for early clinical development of the assets. Before that, Dr. Hu-Lowe was the Senior Director of Strategic Alliance and Program management at Wellspring Biosciences Inc., where she successfully managed both internal discovery and IND-enabling programs, as well as strategic partnership with pharma and academic research entities. Prior to this, Dr. Hu-Lowe spent over 12 years at Pfizer Oncology as a functional group leader (angiogenesis and TME) and research project leader, where she led multiple cross-functional teams advancing programs from preclinical to IND submission/clearance and into clinical development. During her Pfizer tenure, Dr. Hu-Lowe also served as the translational research representative to clinical development programs, directly contributed to the NDA and approvals of axitinib (Inlyta™) and sunitinib (Sutent™) by the U.S. FDA, and was a recipient of the prestigious Pfizer “Career Achievement Award”.

Dr. Hu-Lowe received her undergraduate degree in Chemistry from BNU of China, Ph.D. in Biochemistry from the University of Mississippi and completed her post-doctoral training and academic research track at the Scripps Research Institute and the Burnham Cancer Institute (now the Sanford Burnham Prebys Medical Discovery Institute) with a focus on integrins, extracellular metrix, and angiogenesis.